Company: ERAS
Filing Date: 2025-03-20
Form Type: 10-K
Source: 0000950170-25-042682
Chunk: 281

Company: Erasca, Inc.
Filing Date: 2025-03-20
Form: 10-K
Item: Item 6
Chunk 281
---
297

The accompanying notes are an integral part of these consolidated financial statements.

F-3

Erasca, Inc.

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

    Year Ended December 31,

    2024

    2023

    Operating expenses:

    Research and development
     
    $
    115,359

    $
    103,821

    In-process research and development

    22,500

    —

    General and administrative

    41,728

    37,704

    Total operating expenses

    179,587

    141,525

    Loss from operations

    (179,587
    )

    (141,525
    )

    Other income (expense)

    Interest income

    20,093

    16,712

    Other expense, net

    (2,156
    )

    (229
    )

    Total other income (expense), net

    17,937

    16,483

    Net loss
     
    $
    (161,650
    )
     
    $
    (125,042
    )

    Net loss per share, basic and diluted
     
    $
    (0.69
    )
     
    $
    (0.83
    )

    Weighted-average shares of common stock used in computing net loss per share, basic and diluted

    233,817,916

    150,184,994

    Other comprehensive income (loss):

    Unrealized gain on marketable securities, net

    328

    1,118

    Comprehensive loss
     
    $
    (161,322
    )
     
    $
    (123,924
    )

The accompanying notes are an integral part of these consolidated financial statements.

F-4

Erasca, Inc.

Consolidated Statements of Stockholders’ Equity

(In thousands, except share data)

    Accumulated

    Additional

    Other

    Total

    Common Stock

    Paid-in

    Comprehensive

    Accumulated

    Stockholders'

    Shares

    Amount

    Capital

    Income (Loss)

    Deficit

    Equity

    Balance at December 31, 2022

    150,448,363

    $
    15

    $
    893,850

    $
    (1,041
    )